Modification of biochemical recurrence risk in patients with localized prostate cancer after radical prostatectomy with combined histomorphological changes in the peritumoral zone

Abstract

Aim. To assess the prognostic significance of histopathological processes in the peritumoral zone with respect to the risk of biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.

Methods. Histomorphological studies were conducted in the perifocal area of surgical tissue samples from 309 patients with localized prostate cancer (T1c-2cN0M0) after a radical surgery using light microscopy. Four groups of patients were identified depending on the risk of recurrence. Enzyme immunoassay was used to determine the concentration of prostate-specific antigen in the serum at baseline and every 3 months for two years after the surgery to detect biochemical recurrence.

Results. Histomorphological examination of the peritumoral zone made it possible to identify histopathological processes associated with adenocarcinoma in 257 out of 309 (83.2%) patients with localized prostate cancer. The risk of biochemical recurrence of a combination of prostatic adenocarcinoma and prostatic intraepithelial neoplasia-2 increased by 3.3 (p=0.02), and of a combination of adenocarcinoma, neoplasia and chronic inflammation in the perifocal zone increased by 4.5 times (p=0.005) compared to patients without histopathological changes of the peritumoral zone. In combination of prostate adenocarcinoma with neoplasia and chronic inflammation in the peritumoral zone, the number of patients with an intermediate risk of cancer recurrence after surgical treatment increased due to decrease of the proportion of patients with very low and low risk of recurrence of the oncologic disease.

Conclusion. The combination of prostate cancer with high-grade prostatic intraepithelial neoplasia and chronic inflammation in the peritumoral zone modifies the risk of biochemical recurrence of cancer after radical prostatectomy.

Keywords

prostate cancer / biochemical recurrence / risk / peritumoral zone / prostatic intraepithelial neoplasia

References

[1] Guliev F.A. Predictors of biochemical recurrence of prostate cancer. Kazan medical journal. 2017; 98 (6): 890–894. (In Russ.)

[2] Гулиев Ф.А. Предикторы биохимического прогрессирования рака предстательной железы. Казанский мед. ж. 2017; 98 (6): 890-894. DOI: 10.17750/KMJ2017-890.

[3] Lozhkin E.A., Sukhanov S.A., Kir’yanov N.A. New criteria of morphological assessment of the prognosis of the prostate cancer. Ural'skiy meditsinskiy zhurnal. 2017; (4): 70–72. (In Russ.)

[4] Ложкин Е.А., Суханов С.А., Кирьянов Н.А. Новые критерии морфологической оценки прогноза рака предстательной железы. Уральский мед. ж. 2017; (4): 70-72.

[5] Yurmazov Z.A. Place of PIN in tumor pathology of the prostate gland. Sibirskiy onkologicheskiy zhurnal. 2009; (suppl. 1): 224–225. (In Russ.)

[6] Юрмазов З.А. Место ПИН в опухолевой патологии предстательной железы. Сибирский онкол. ж. 2009; (прил. 1): 224-225.

[7] Bostwick D.G. Progression of prostatic intra­epitelial neoplasia to early invasive adenocarcinoma. Eur. Urol. 1996; 30: 145–152. PMID: 8875195.

[8] Bostwick D.G. Progression of prostatic intraepitelial neoplasia to early invasive adenocarcinoma. Eur. Urol. 1996; 30: 145-152. PMID: 8875195.

[9] Allina D.O., Andreeva Yu.Yu., Zavalishina L.E. et al. High-grade prostatic intraepithelial neoplasia: State-of-the-art. Arkhiv patologii. 2015; (1): 69–74. (In Russ.)

[10] Аллина Д.О., Андреева Ю.Ю., Завалишина Л.Э. и др. Простатическая интраэпителиальная неоплазия высокой степени: современное состояние проблемы. Архив патол. 2015; (1): 69-74. DOI: 10.17116/patol201577169-.

[11] Gorbunova E.N., Davydova D.A., Krupin V.N. Chronic inflammation and fibrosis as risk factors of the prostatic intraepithelial neoplasia and prostate cancer. Sovremennye tekhnologii v meditsine. 2011; (1): 79–83. (In Russ.)

[12] Горбунова Е.Н., Давыдова Д.А., Крупин В.Н. Хроническое воспаление и фиброз как факторы риска простатических интраэпителиальных неоплазий и рака предстательной железы. Соврем. технол. мед. 2011; (1): 79-83.

[13] Yurmazov Z.A., Vasil'ev N.V. Clinical and morphological features of prostate cancer in combination with PIN. Sibirskiy onkologicheskiy zhurnal. 2010; (suppl. 1): 118. (In Russ.)

[14] Юрмазов З.А., Васильев Н.В. Клинические и морфологические особенности рака предстательной железы в сочетании с ПИН. Сибирский онкол. ж. 2010; (прил. 1): 118.

[15] Bova F.S., Kit O.I., Maksimov A.Yu., Dimitriadi S.N. The association of prostatic intraepithelial neoplasia of high degree in the peritumoral zone with recurrence after radical prostatectomy in patients with localized prostate cancer. Prakticheskaya meditsina. 2017; (10): 108–112. (In Russ.)

[16] Бова Ф.С., Кит О.И., Максимов А.Ю., Димитриади С.Н. Связь простатической интраэпителиальной неоплазии высокой степени в перитуморальной зоне с рецидивированием после радикальной простатэктомии у больных локализованным раком предстательной железы. Практич. мед. 2017; (10): 108-112.

[17] D'Amico A.V., Whittington R., Malkowicz S.B. et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology. 1997; 49 (suppl. 3A): 23–30. DOI: 10.1016/S0090-4295(97)00165-9.

[18] D'Amico A.V., Whittington R., Malkowicz S.B. et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology. 1997; 49 (suppl. 3A): 23-30. DOI: 10.1016/S0090-4295(97)00165-9.

[19] Dennis L.K., Lynch C.F., Torner J.C. Epi­demiologic association between prostatitis and prostate cancer. Urology. 2002; 60: 78–83. DOI: 10.1016/S0090-4295(02)01637-0.

[20] Dennis L.K., Lynch C.F., Torner J.C. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002; 60: 78-83. DOI: 10.1016/S0090-4295(02)01637-0.

[21] Corn P.G. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag. Res. 2012; 4: 183–193. DOI: 10.2147/CMAR.S32839.

[22] Corn P.G. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag. Res. 2012; 4: 183-193. DOI: 10.2147/CMAR.S32839.

[23] Mc Neal J.E. Origin and development of carcinoma in the prostate. Cancer. 1969; 23: 24–34. DOI: 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1.

[24] Mc Neal J.E. Origin and development of carcinoma in the prostate. Cancer. 1969; 23: 24-34. DOI: 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1.

[25] Platz E.A., Kulac I., Barber J., de Marzo A.M. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT cohorts. Cancer Epidemiol. Biomarkers Prev. 2017; 26 (10): 1549–1557. DOI: 10.1158/1055-9965.EPI-17-0503.

[26] Platz E.A., Kulac I., Barber J., de Marzo A.M. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT cohorts. Cancer Epidemiol. Biomarkers Prev. 2017; 26 (10): 1549-1557. DOI: 10.1158/1055-9965.EPI-17-0503.

[27] Aliev M.D., Bohyan B.Yu., Burov D.A. Prognostic role of margin resection in surgery with soft tissue sarcomas. Prakticheskaya onkologiya. 2013; 14 (2): 97–100. (In Russ.)

[28] Алиев М.Д., Бохян Б.Ю., Буров Д.А. Прогностическая роль края резекции в хирургии сарком мягких тканей. Практич. онкол. 2013; 14 (2): 97-100. .

RIGHTS & PERMISSIONS

Bova F.S., Kit O.I., Maksimov A.Y., Karnaukhov N.S.